GAITHERSBURG, MD -- (Marketwire) -- 12/07/12 -- Cytomedix, Inc. (OTCQX: CMXI) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that positive data on the Angel® cPRP system in a veterinary application -- treatment of persistent mating induced endometritis (PMIE) in mares -- were recently presented at the 3rd annual conference of the North American Veterinary Regenerative Medicine Association (NAVRMA) in Savannah, GA. Treatment with PRP was shown to be associated with a statistically significant reduction in certain endometrial pro-inflammatory cytokines and inducible nitric oxide synthetase (iNOS), both known to be involved in the pathology of PMIE.
Many mares fail to respond to conventional therapies and recent studies have shown a link between PMIE and the expression of certain cytokines. Nitric oxide is also believed to play a role in uterine clearance. The study investigated 9 barren mares with a history of PMIE. During the treatment cycle, whole blood was processed using the Angel cPRP system and the resultant PRP was brought to a final volume with platelet poor plasma and infused into the uterus. All mares were then inseminated with motile sperm. Evaluation of endometrial biopsies showed that in mares treated with PRP there was down-regulated expression of pro-inflammatory molecules, IL-1b, IL-6, IL-8 and iNOS, compared with untreated mares (p < 0.05).
Lisa Metcalf MS, DVM, Diplomate ACT, lead investigator on the study commented on the results, "Infertility in high value mares is a significant economic problem in the equestrian industry. Intra uterine treatment with PRP offers a new approach to treating this condition and, in this study we observed multiple pregnancies in the treated mares that were previously barren. Use of PRP in this setting warrants further investigation".
Martin Rosendale, Chief Executive Officer of Cytomedix added, "These results are very promising and give us further insight into the mechanism by which PRP inhibits inflammation by decreasing the presence of pro-inflammatory cytokines. These findings regarding the control of inflammation may be transferable to human inflammatory conditions. We will continue to explore disease areas where inflammation is known to play a role and where there is a need for a therapeutic alternative to corticosteroids."
About Cytomedix, Inc.
Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies for tissue repair. The Company markets the AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds and the Angel® Concentrated Platelet Rich Plasma System, a blood processing device and disposable products used for the separation of whole blood or a mixture of blood and bone marrow, into red cells, platelet poor plasma ("PPP") and PRP in surgical settings On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit cytomedix.com
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.